Bill > HB1063

This bill addresses the potential medical use of a specific form of psilocybin (a psychedelic compound) for treating treatment-resistant depression. The bill begins by highlighting the significant public health challenges associated with treatment-resistant depression, particularly among veterans, noting that approximately one-third of people with major depressive disorder do not respond to standard medications. The legislation proposes to modify Colorado's controlled substances law to allow for the use of FDA-approved crystalline polymorph psilocybin, which has shown promising results in clinical trials for reducing depression scores. Specifically, the bill would create an exception to the current Schedule I drug classification for psilocybin when it is an FDA-approved prescription medication, ensuring that such a medication would be controlled in Colorado consistent with its federal scheduling. The bill aims to enable behavioral health professionals in Colorado to potentially prescribe this medication if and when the FDA approves it for prescription use, providing a potential new treatment option for patients with treatment-resistant depression. The legislation would take effect after the standard 90-day legislative period, with the potential for a public referendum in November 2026 if challenged.

Health and Social Services

https://leg.colorado.gov/bills/hb25-1063